Compare Comfort Systems USA Inc (FIX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs TG Therapeutics Inc — how do they compare? Comfort Systems USA Inc trades at $1,756.3 (market cap $59.41B), while TG Therapeutics Inc trades at $49.77 (market cap $7.64B). The key difference: Comfort Systems USA Inc is far larger — about 7.8× TG Therapeutics Inc's market cap, and Comfort Systems USA Inc pays a 0.21% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FIX | TGTX | |
|---|---|---|
Market Cap | $59.41B | $7.64B |
Sector | Technology | Health |
52-Week High | $2.07K | $59.06 |
52-Week Low | $680.86 | $26.94 |
Enterprise Value | $57.88B | $7.84B |
Dividend Yield | 0.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIX trades at $1,752.98, up 4.67% in 24 hours, with a bearish technical signal but strong fundamentals including a 12.78% net income margin and 55.29% ROE. Recent earnings beats and a record backlog driven by AI-data center demand highlight growth, though valuation ratios like a P/E of 41.55 suggest premium pricing. The stock faces resistance near $1,754 with support at $1,633.
Outlook is positive due to robust earnings growth and analyst buy consensus, but risks include high valuation, execution challenges, and market volatility. Upside to the $2,170 consensus price target depends on sustained margin expansion and backlog conversion.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
